ZYNTEGLO is indicated for the treatment of patients 12 years and older with transfusion-dependent β-thalassaemia (TDT) who do not have a β⁰/β⁰ genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but an HLA-matched related HSC donor is not available.

Approved for patients in the European Union, Iceland, Liechtenstein, Norway and UK.